
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $8.1B · as of 2026-06-29
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| ALK HDM tablet | Phase 3 | Asthma |
| MK-8237 6 DU | Phase 2 | Rhinitis, Allergic, Perennial |
| AVANZ Salsola | Phase 2 | Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen |
| ALK Grass tablet - use of compliance device | Phase 3 | Allergy |
| AVANZ Phleum pratense 15,000 SQ+ | Phase 2 | Grass Pollen Induced Allergic Rhinoconjunctivitis |
| Sublingual allergy immunotherapy tablet | Phase 3 | Allergic Rhinitis Due to Dermatophagoides Farinae |
| AVANZ Phleum pratense | Phase 3 | Allergic Rhinoconjunctivitis |
| Grass (Phleum pratense) pollen allergen extract | Phase 3 | Rhinitis Allergic |
| AIT Tablet | Phase 3 | House Dust Mite Allergy |
| Specific allergen immunotherapy | Phase 2 | Cat Allergy |
| Ambrosia artemisiifolia allergen extract (Amb a 1-U) | Phase 3 | Rhinitis, Allergic |
| ALK Grass tablet | Phase 3 | Allergy |
| Grazax + Aerius | Phase 3 | Allergic Rhinoconjunctivitis |
| Loratadine 10 mg Rescue Treatment | Phase 3 | Rhinoconjunctivitis |
| SCH 39641 | Phase 3 | Allergy |
| Allergy vaccination (Alutard SQ) | Phase 3 | Allergy |
| subcutaneous immunotherapy | Phase 3 | Atopic Dermatitis |
| Pangramin SLIT HDM mix. | Phase 3 | Allergic Rhinitis |
| HDM SLIT-tablet | Phase 3 | Allergic Rhinitis |
| Tree SLIT-tablet | Phase 3 | Allergy |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.